Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical StudiesSystematic Review Published on 2021-12-252022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI AstraZeneca B.1.617.2 clinical CoronaVac COVID-19 COVID-19 infection COVID-19 vaccines database datasets death Delta delta variant dose Effectiveness Efficacy first dose highest Hospitalization include Infection lack limitation Meta-analysis Moderna morbidity Mortality mRNA-based vaccines observational studies Pfizer-BioNTech promote public health raised review SARS-CoV-2 SARS-CoV-2 B.1.617.2 variant vaccines SARS-CoV-2 variants searched second dose Severe infection Side effect Support supported the SARS-CoV-2 Transmissibility vaccination rate Vaccine Vaccines variant variants Web of Science [DOI] 10.3390/vaccines10010023 PMC 바로가기 [Article Type] Systematic Review
Which Vaccine? The Cost of Religious Freedom in Vaccination PolicyOriginal Research Published on 2021-12-232022-10-29 Journal: Journal of bioethical inquiry [Category] COVID-19, SARS, [키워드] approved arise Catholic cell line condition connection country COVID-19 COVID-19 vaccine Effectiveness Moderna pandemic ethics Pfizer/BioNTech Policy public health receive Religious freedom risk significant difference state the vaccine vaccination vaccination ethics Vaccine Vaccines [DOI] 10.1007/s11673-021-10148-6 PMC 바로가기 [Article Type] Original Research
Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single CenterMedicine Published on 2021-12-232022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age Antigen association attacked AZD1222 baseline benefit biologics center Comorbidities contraindication Control control group COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines disease Disease activity dose Exacerbation fatality fluctuation genotypes HLA human leukocyte antigen immunized individual leukocyte mechanism Moderna mRNA-1273 pandemic era Patient patients physician pre-vaccination psoriasis psoriatic arthritis receiving recruited report reported Severe COVID-19 Infection severity Sex Th17 Th17 cell therapy treatable vaccinated against COVID-19 vaccination Vaccine Vaccines worsening [DOI] 10.3389/fmed.2021.812010 PMC 바로가기 [Article Type] Medicine
Analysis of COVID-19 Vaccine Type and Adverse Effects Following VaccinationResearch Published on 2021-12-222022-10-29 Journal: JAMA Network Open [Category] COVID-19, SARS, [키워드] 95% CI Adverse adverse effect adverse effects age allergic reaction Analysis anaphylaxis BNT162b2 candidate Cohort cohort study comparison Complete COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine dose drug Effect evaluate events exposure Factor female finding greater Health Importance include independent individual IQR JNJ-78436735 Johnson & Johnson measure mechanism median Medical conditions Moderna mRNA-1273 mRNA-1273 vaccine multivariable logistic regression objective Odds ratio of BNT162b2 Older participant Pfizer/BioNTech Point provided Relevance reported Result Science serious COVID-19 setting severity Sex Substance use Surveillance Type vaccination Vaccine vaccine dose with COVID-19 women [DOI] 10.1001/jamanetworkopen.2021.40364 PMC 바로가기 [Article Type] Research
Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reportsRandomized Controlled Trial Published on 2021-12-202022-10-04 Journal: BMC Infectious Diseases [Category] SARS, 임상, [키워드] 1:1 BCG BCG scar BCG vaccination Case report caused characteristic childhood children COVID-19 cross-reaction cross-reactivity described disease disease entity dose enrolled female HCW Health care worker Inclusion Influenza itching Moderna mRNA mRNA Covid-19 vaccination mRNA vaccination mRNA vaccine Neonatal offered Older participant Pathogenesis Pfizer-BioNTech provide provided Randomized randomized trial Randomly Reactivation receiving reported risk SARS-CoV-2 scar second dose secretion Symptom Treatment Trial trial participant vaccination Vaccine viral infection women [DOI] 10.1186/s12879-021-06949-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성Clinical Trial Published on 2021-12-182022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, [키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type [DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control studySARS-CoV-2의 델타, 뮤 및 기타 새로운 변이체에 대한 mRNA-1273의 효과: 테스트 음성 사례-대조군 연구Article Published on 2021-12-152022-09-11 Journal: The BMJ [Category] Fulltext, SARS, 변종, [키워드] 95% confidence interval age Alpha Analysis calculated case-control study confounders Control controls COVID-19 vaccination declined delta variant dose effective Effectiveness evaluate Healthcare system Hospital admission Infection infection with SARS-CoV-2 less Logistic regression Moderna mRNA mRNA-1273 mRNA-1273 vaccine negative controls negative test outcome positive Positive test SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Sequencing Sex specimen specimen collection Test test negative vaccination Vaccine variant variants was used whole genome Whole genome sequencing [DOI] 10.1136/bmj-2021-068848 PMC 바로가기 [Article Type] Article
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple SclerosisArticle Published on 2021-12-112022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-CD20 therapy anti-CD20 treatment Antibody titer B cell depletion B-cell BNT162b2 vaccine CD20 clinically COVID-19 Depleted dose homologous humoral immune response IgG IgG antibody IgG response immunization individual infections lack median time Moderna mRNA mRNA vaccine mRNA-1273 mRNA-based vaccine Multiple outcome Patient Protective quantified response risk factor SARS-CoV-2 SARS-CoV-2 vaccine sclerosis Seroconversion seroconverted spike receptor-binding domain T-cell Response treated vaccination [DOI] 10.3390/vaccines9121470 PMC 바로가기 [Article Type] Article
First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case reportCase Report Published on 2021-12-112022-10-28 Journal: BMC Nephrology [Category] COVID-19, SARS, [키워드] Acute kidney injury addition Admission alteration antibody Case report Corticosteroid COVID-19 vaccines described Diagnosis diagnostic differential diagnosis disintegrin dose excluded Fever Final first dose first symptom headache Hematuria Hemolysis hemolytic anemia immune initial initiated malaise male Mild Moderna motif mRNA-1273 mRNA-based nausea neurological normalized pathophysiological Patient petechial bleeding plasma exchange Platelet purpura receive receiving reported resolved SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Symptom the patient therapy thrombocyte thrombocytopenia thrombotic Thrombotic thrombocytopenic Thrombotic thrombocytopenic purpura USA vaccination Vaccine Vaccines vomiting while [DOI] 10.1186/s12882-021-02616-3 PMC 바로가기 [Article Type] Case Report
Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid시티디닐/양이온 지질을 사용한 mRNA 전달 시스템의 합리적인 준비 및 적용Article Published on 2021-12-102022-09-11 Journal: Journal of controlled release : official journal o [Category] SARS, 치료기술, [키워드] acetamide Adaptive immune response adverse event approved Cationic lipid cell immunity CLD Combination coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA vaccine cytoplasm Efficacy and safety electrostatic encapsulate Formulation H-bonding immunized mice induce interactions intramuscular Lipid lipids Lipoplexes Messenger RNA Mild Moderna mRNA mRNA delivery. mRNA vaccines Neutral Neutralizing antibodies neutralizing antibody nucleotide outbreak Pfizer-BioNTech propanoate reported robust shown single nucleotide stimulate therapy [DOI] 10.1016/j.jconrel.2021.10.023 PMC 바로가기 [Article Type] Article